Polar Asset Management Partners Inc. Buys New Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Polar Asset Management Partners Inc. acquired a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 88,100 shares of the company's stock, valued at approximately $2,071,000. Polar Asset Management Partners Inc. owned 0.17% of Tyra Biosciences at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company's stock worth $14,757,000 after buying an additional 140,833 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Tyra Biosciences by 32.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company's stock worth $929,000 after purchasing an additional 14,352 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company's stock worth $377,000 after purchasing an additional 2,574 shares during the period. American Century Companies Inc. lifted its stake in Tyra Biosciences by 582.9% in the second quarter. American Century Companies Inc. now owns 170,283 shares of the company's stock valued at $2,723,000 after purchasing an additional 145,346 shares during the last quarter. Finally, Ensign Peak Advisors Inc bought a new position in Tyra Biosciences during the second quarter valued at $3,047,000. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Trading Up 3.7 %

Shares of Tyra Biosciences stock traded up $0.56 on Friday, reaching $15.73. The stock had a trading volume of 597,165 shares, compared to its average volume of 196,068. The business's 50 day moving average is $19.45 and its two-hundred day moving average is $19.71. Tyra Biosciences, Inc. has a 1 year low of $11.24 and a 1 year high of $29.60. The company has a market cap of $795.99 million, a P/E ratio of -9.42 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, equities analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Insider Activity at Tyra Biosciences

In other Tyra Biosciences news, Director Nina S. Kjellson sold 27,493 shares of Tyra Biosciences stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $16.56, for a total transaction of $455,284.08. Following the completion of the sale, the director now directly owns 458,506 shares in the company, valued at $7,592,859.36. The trade was a 5.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Todd Harris sold 5,698 shares of the business's stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $24.31, for a total transaction of $138,518.38. Following the completion of the transaction, the chief executive officer now directly owns 1,496,729 shares of the company's stock, valued at approximately $36,385,481.99. This represents a 0.38 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 101,050 shares of company stock valued at $2,235,492. Company insiders own 15.40% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on TYRA shares. HC Wainwright lowered their target price on Tyra Biosciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research note on Monday, November 11th. Piper Sandler initiated coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an "overweight" rating and a $33.00 price objective on the stock. Bank of America upgraded shares of Tyra Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. Oppenheimer boosted their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an "outperform" rating in a research report on Thursday, September 19th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $28.00 price objective on shares of Tyra Biosciences in a report on Friday, October 25th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $31.00.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.